Key Action and Date
The Board of Directors of Jagsonpal Pharmaceuticals Limited, at its meeting held on June 25, 2026, approved the appointment of Mr. Anil Kumar Matai (DIN: 03122685) as an Additional Director in the category of Non-Executive Independent Director.
Effective Date and Term
The appointment is effective from June 25, 2026. The term of his appointment as an Independent Director will be for a period of 5 (Five) years.
Condition of Appointment
The appointment is subject to the approval of the shareholders of the Company.
Board Meeting Details
The Board Meeting commenced at 4:45 p.m. and concluded at 5:30 p.m. on June 25, 2026.
Director Profile and Experience
Mr. Anil Kumar Matai is a seasoned life sciences leader with over 35 years of experience across multinational corporations, Indian pharma companies, and private equity. He is currently serving as the Director General of OPPI (Organisation of Pharmaceutical Producers of India). His career includes senior leadership roles such as CEO of Novartis India Ltd., President & MD of Zydus Healthcare Ltd., and Operating Partner at Jashvik Capital. His experience spans pharmaceuticals, healthcare, consumer sectors, and manufacturing.
Regulatory Affirmation
The company affirms that Mr. Anil Kumar Matai is not debarred or disqualified from being appointed as a Director by SEBI, the Ministry of Corporate Affairs, or any other statutory authority.
Relationships Disclosure
There are no inter-se relationships between Mr. Anil Kumar Matai and the other members of the Board.
Compliance Reference
The disclosure is made with reference to SEBI master circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.